J. Saruwatari, T. Ishitsu, Takayuki Seo, Masatsugu Shimomasuda, Yusuke Okada, Shuji Goto, R. Nagata, Ayaka Takashima, Shiho Yoshida, Shuichi Yoshida, N. Yasui‐Furukori, S. Kaneko, K. Nakagawa
{"title":"细胞色素P450多态性对抗癫痫药物治疗的临床影响","authors":"J. Saruwatari, T. Ishitsu, Takayuki Seo, Masatsugu Shimomasuda, Yusuke Okada, Shuji Goto, R. Nagata, Ayaka Takashima, Shiho Yoshida, Shuichi Yoshida, N. Yasui‐Furukori, S. Kaneko, K. Nakagawa","doi":"10.3805/EANDS.3.34","DOIUrl":null,"url":null,"abstract":"The goal of pharmacogenetics is to deliver safe and effective drug therapy. Genetic polymorphisms in cytochrome P450 (CYP) enzyme genes are implicated in the inter-individual variability in pharmacokinetics of antiepileptic drugs (AEDs). However, the clinical impact of CYP polymorphisms on AED therapy remains controversial. Previous studies have shown that the defective CYP2C9 alleles affect the required dose of phenytoin and the risk of its toxicity. We have reported that the CYP2C19-deficient genotype is associated with the serum concentration of an active metabolite of clobazam, N-desmethylclobazam, and with the clinical efficacy of clobazam therapy. We determined also the influence of polymorphisms in CYP genes on the population pharmacokinetic parameters of AEDs us-","PeriodicalId":39430,"journal":{"name":"Epilepsy and Seizure","volume":"3 1","pages":"34-50"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3805/EANDS.3.34","citationCount":"8","resultStr":"{\"title\":\"The clinical impact of cytochrome P450 polymorphisms on anti-epileptic drug therapy\",\"authors\":\"J. Saruwatari, T. Ishitsu, Takayuki Seo, Masatsugu Shimomasuda, Yusuke Okada, Shuji Goto, R. Nagata, Ayaka Takashima, Shiho Yoshida, Shuichi Yoshida, N. Yasui‐Furukori, S. Kaneko, K. Nakagawa\",\"doi\":\"10.3805/EANDS.3.34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The goal of pharmacogenetics is to deliver safe and effective drug therapy. Genetic polymorphisms in cytochrome P450 (CYP) enzyme genes are implicated in the inter-individual variability in pharmacokinetics of antiepileptic drugs (AEDs). However, the clinical impact of CYP polymorphisms on AED therapy remains controversial. Previous studies have shown that the defective CYP2C9 alleles affect the required dose of phenytoin and the risk of its toxicity. We have reported that the CYP2C19-deficient genotype is associated with the serum concentration of an active metabolite of clobazam, N-desmethylclobazam, and with the clinical efficacy of clobazam therapy. We determined also the influence of polymorphisms in CYP genes on the population pharmacokinetic parameters of AEDs us-\",\"PeriodicalId\":39430,\"journal\":{\"name\":\"Epilepsy and Seizure\",\"volume\":\"3 1\",\"pages\":\"34-50\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3805/EANDS.3.34\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epilepsy and Seizure\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3805/EANDS.3.34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsy and Seizure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3805/EANDS.3.34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
The clinical impact of cytochrome P450 polymorphisms on anti-epileptic drug therapy
The goal of pharmacogenetics is to deliver safe and effective drug therapy. Genetic polymorphisms in cytochrome P450 (CYP) enzyme genes are implicated in the inter-individual variability in pharmacokinetics of antiepileptic drugs (AEDs). However, the clinical impact of CYP polymorphisms on AED therapy remains controversial. Previous studies have shown that the defective CYP2C9 alleles affect the required dose of phenytoin and the risk of its toxicity. We have reported that the CYP2C19-deficient genotype is associated with the serum concentration of an active metabolite of clobazam, N-desmethylclobazam, and with the clinical efficacy of clobazam therapy. We determined also the influence of polymorphisms in CYP genes on the population pharmacokinetic parameters of AEDs us-
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
